Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- How Will Party’s Return Affect Healthcare and Drug Policy? LDP Back in Power for First Time in 3 Years
January 17, 2013
- MHLW to Launch Panel by Jan.-End to Discuss New Rule for Online OTC Drug Sales after Top Court Ruling
January 16, 2013
- MHLW to Make HPV, Hib, and Pneumococcal Vaccines Mandatory, Excluding Them from the FY2012 Extra Budget
January 16, 2013
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
- Supreme Court OKs Online Sales of OTC Drugs, Rejects Govt Appeal
January 15, 2013
- MHLW Calls for Preventive Measures against Accidental Ingestion of Pharmaceutical Products by Children
January 15, 2013
- Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
- MHLW Revises GCP Ordinance, Pushes Clinical Trials with Simple Contract Procedures
January 11, 2013
- PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
- MHLW’s Revised Budget Request for FY2013 under LDP for Innovation-Related Spending 40% Less than under DPJ
January 11, 2013
- MHLW Approves 2 Switch OTC Versions of Epadel
January 7, 2013
- MHLW Survey Finds Nearly 10% of Doctors Who Prescribe Prazaxa Are Unaware of Warnings in Blue Letter
December 28, 2012
- MHLW Compiling Database of Drug Approvals Overseas
December 28, 2012
- PMDA Review Period Reduced for Both Priority, Standard Products
December 28, 2012
- 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
- MHLW Approves 23 Products Including Toviaz
December 26, 2012
- LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
- OTC Switching of Life Style Disease Treatments on Different Level from that of Conventional Treatments: JMA Vice President Nakagawa
December 25, 2012
- MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
- Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…